Get the Stockscreener App
0.3676
2.35%
-0.0075
Leap Therapeutics Inc stock is traded at $0.3676, with a volume of 378.22K.
It is down -2.35% in the last 24 hours and up +13.06% over the past month.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
See More
Previous Close:
$0.3751
Open:
$0.3738
24h Volume:
378.22K
Relative Volume:
0.18
Market Cap:
$15.85M
Revenue:
$1.50M
Net Income/Loss:
$-64.59M
P/E Ratio:
-0.2201
EPS:
-1.67
Net Cash Flow:
$-55.17M
1W Performance:
+9.31%
1M Performance:
+13.06%
6M Performance:
-87.79%
1Y Performance:
-87.06%
1-Day Range:
$0.3386
$0.3794
1-Week Range:
$0.3301
$0.3904
52-Week Range:
$0.2223
$4.79
Leap Therapeutics Inc Stock (LPTX) Company Profile
Name
Leap Therapeutics Inc
Sector
Industry
Phone
617 252 4343
Address
47 THORNDIKE STREET, CAMBRIDGE, MA
Compare LPTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LPTX
Leap Therapeutics Inc
|
0.3676 | 15.85M | 1.50M | -64.59M | -55.17M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.22 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.92 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
543.71 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
267.42 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
223.94 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Leap Therapeutics Inc Stock (LPTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-29-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-04-21 | Initiated | Mizuho | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Jun-29-20 | Initiated | Piper Sandler | Overweight |
| Feb-11-20 | Initiated | Robert W. Baird | Outperform |
| Nov-15-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-13-19 | Resumed | Raymond James | Outperform |
| Mar-07-17 | Initiated | Ladenburg Thalmann | Buy |
View All
Leap Therapeutics Inc Stock (LPTX) Latest News
Cash-strapped Cambridge cancer biotech halves workforce - The Business Journals
Leap Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Leap Therapeutics Q1 Net Income USD -15.435 Million - marketscreener.com
Leap Therapeutics Reports First Quarter 2025 Financial Results | - GuruFocus
Leap Therapeutics, Inc. (LPTX) Q1 Loss Beats Estimates - Nasdaq
Leap Therapeutics Reports First Quarter 2025 Financial Results - PR Newswire
LEAP THERAPEUTICS, INC. SEC 10-Q Report - TradingView
Purple Biotech Appoints Shai Lankry as Chief Financial Officer - The Manila Times
Leap Therapeutics (LPTX) Expected to Announce Quarterly Earnings on Monday - Defense World
Leap Therapeutics Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Closing Bell Recap: Leap Therapeutics Inc (LPTX) Ends at 0.34, Reflecting a -12.39 Downturn - DWinneX
LPTX’s Market Whiplash: -85.46% YTD Decline, 37.04% Rise in 30 Days - investchronicle.com
75,800 Shares in Leap Therapeutics, Inc. (NASDAQ:LPTX) Acquired by LPL Financial LLC - Defense World
Quarterly Snapshot: Quick and Current Ratios for Leap Therapeutics Inc (LPTX) - DWinneX
Leap Therapeutics to Present Preclinical Data of FL-501, a Novel - GuruFocus
Novel Cancer Cachexia Drug FL-501 Shows 3X Better Half-Life in Preclinical Data | LPTX Stock News - Stock Titan
Metastatic Colorectal Cancer Market Poised for Expansion Across the 7MM During the Forecast Period (2025-2034) as Breakthrough Therapies Gain Traction | DelveInsight - PR Newswire UK
Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatam - GuruFocus
Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer | LPTX Stock News - GuruFocus
Leading Oncologist Reveals Game-Changing Phase 2 Results for Advanced Colorectal Cancer Treatment - Stock Titan
Leap Therapeutics stock hits 52-week low at $0.28 amid downturn - Investing.com Canada
Leap Therapeutics stock hits 52-week low at $0.28 amid downturn By Investing.com - Investing.com South Africa
BlossomHill Therapeutics to Present the Design and Discovery of BH-30643, the Company’s OMNI-EGFR™ Inhibitor, at the 2025 AACR Annual Meeting - Business Wire
HC Wainwright Expects Reduced Earnings for Leap Therapeutics - Defense World
Leap Therapeutics (NASDAQ:LPTX) Earns Neutral Rating from HC Wainwright - The AM Reporter
HC Wainwright Reiterates Neutral Rating for Leap Therapeutics (NASDAQ:LPTX) - Defense World
H.C. Wainwright maintains neutral on Leap Therapeutics stock By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Leap reports progress in colorectal cancer study By Investing.com - Investing.com South Africa
Driving the Future of Healthcare HIT, OSRH, THTX, LPTX, CSDX, Innovations in Health Insurance, Virtual Care, Oncology, and Chronic Disease Treatment - Financial Content
Micro Cap Soars Following Preliminary Data Update - The Globe and Mail
Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer - Yahoo
LEAP THERAPEUTICS Earnings Results: $LPTX Reports Quarterly Earnings - Nasdaq
Leap Therapeutics Says New Data Show Sirexatamab Improves Survival in Colorectal Cancer Trial - MarketScreener
Leap Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study - MarketScreener
Leap Therapeutics Reports Positive DeFianCe Phase 2 Data Of Sirexatamab In Colorectal Cancer - Nasdaq
Leap Therapeutics Reports Fourth Quarter And FY 2024 Results - Marketscreener.com
Leap reports progress in colorectal cancer study - Investing.com India
Breakthrough: Leap's Colorectal Cancer Drug Delivers 32% Higher Response Rate in Latest Trial - Stock Titan
Tobacco Control Has Saved Nearly 4 Millions Lives, Study Estimates - 69News WFMZ-TV
Leap Therapeutics stock hits 52-week low at $0.39 - Investing.com
Leap Therapeutics stock hits 52-week low at $0.39 By Investing.com - Investing.com UK
LEAP THERAPEUTICS Earnings Preview: Recent $LPTX Insider Trading, Hedge Fund Activity, and More - Nasdaq
Leap Therapeutics stock hits 52-week low at $0.4 amid sharp decline - Investing.com India
Leap Therapeutics stock hits 52-week low at $0.4 amid sharp decline By Investing.com - Investing.com South Africa
Atossa Therapeutics plans to develop durg to treat advanced breast cancer, talks with FDA on other uses - Marketscreener.com
Sun Pharma's Strategic Leap: Acquiring Checkpoint Therapeutics - Devdiscourse
Checkpoint Therapeutics Shares Leap Premarket on Takeover by Sun Pharma -March 10, 2025 at 06:24 am EDT - Marketscreener.com
Leap Therapeutics (LPTX) to Release Quarterly Earnings on Monday - Defense World
Gastric Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Leap Therapeutics Inc Stock (LPTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.19%
0.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):